HPV-negative OPSCC (n = 21) | |||||
---|---|---|---|---|---|
 | Benign (n = 15) | Malignant (n = 6) | P1 | P2 | P3 |
SUV1 | 1.7 (1.3–2.1; 0.8) | 4.1 (2.2–4.7; 2.5) | 0.02 |  |  |
SUV2 | 1.5 (1.2–1.8; 0.6) | 5.2 (2.2–6.0; 3.8) | 0.016 | 0.02 | 0.07 |
RI | − 14.1 (− 18.9–0.0; 18.9) | 20.0 (− 0.4–31.8; 32.2) | 0.006 |  |  |
HPV-associated OPSCC (n = 32) | |||||
---|---|---|---|---|---|
 | Benign (n = 29) | Malignant (n = 3) | P1 | P2 | P3 |
SUV1 | 1.8 (1.5–2.2; 0.7) | 2.2a | 0.17 |  |  |
SUV2 | 1.8 (1.5–2.3; 0.8) | 2.4a | 0.26 | 0.93 | 1 |
RI | − 0.5 ( − 5.5–11.8; 17.3) | − 0.5a | 0.67 |  |  |